India Cuts Off Exports of Chloroquine To the United States
Nearly half the supply of hydroxychloroquine to the U.S. comes from makers in India, a flow that has now been abruptly stanched after the Asian nation banned exports of all forms of the malaria drug touted by President Donald Trump as a “game changer” for treating the coronavirus.
According to data compiled by Bloomberg Intelligence, 47% of the U.S. supply of the drug last year came from India makers.
Only a handful of suppliers in the top 10 are non-Indian, such as Actavis, now a subsidiary of Israeli generics giant Teva Pharmaceutical Industries Ltd. It’s likely that some of their production facilities are nevertheless located in India, the biggest maker of generic drugs in the world.
India’s export ban on the drug is aimed at ensuring it has enough supply for domestic use after the American president’s endorsement sparked global stockpiling of the medication.
As the coronavirus pandemic widens globally, countries competing for supplies have enacted export bans or restrictions on goods from rice in Vietnam to face masks in Germany.
4 comments:
We shouldnt have outsourced essentials in thr first place.
Epa was right the whole time. He was slamming that point for years.
Globalism is being revealed to be a dangerous fraud.
Hello.....POTUS has spoken with Modi who will send the drug here.
Oh that is good to know. Thanks.
Post a Comment